Ufnal Marcin, Pham Kinga
Department of Experimental Physiology and Pathophysiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland.
Department of Experimental Physiology and Pathophysiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland.
Med Hypotheses. 2017 Jan;98:35-37. doi: 10.1016/j.mehy.2016.11.012. Epub 2016 Nov 24.
Recent studies suggest that blood-borne metabolites of gut microbiota, such as trimethylamine N-oxide (TMAO) are involved in the aetiology of cardiovascular diseases and may serve as markers of cardiovascular risk. To enter the bloodstream the microbiota-derived molecules need to pass the gut-blood barrier (GBB). The GBB plays an important role in maintaining organism homeostasis. It is a complex multi-layer system which determines the absorption of nutrients, water and many other substances. The integrity and permeability of the GBB may be impaired in numerous diseases including gastrointestinal, metabolic and cardiovascular diseases. Here, we propose that the evaluation of the GBB permeability may have a significant diagnostic potential in cardiovascular and metabolic diseases. Second, we suggest that the GBB permeability is a variable that confounds diagnostic value of new gut microbiota-derived biomarkers such as TMAO. Therefore, cardiovascular risk assessment requires the evaluation of both TMAO and the GBB permeability.
最近的研究表明，肠道微生物群的血液传播代谢产物，如氧化三甲胺（TMAO），参与了心血管疾病的病因学，并可能作为心血管风险的标志物。微生物群衍生的分子要进入血液，需要穿过肠-血屏障（GBB）。GBB在维持机体稳态中起重要作用。它是一个复杂的多层系统，决定了营养物质、水和许多其他物质的吸收。GBB的完整性和通透性可能在包括胃肠道、代谢和心血管疾病在内的多种疾病中受损。在此，我们提出，评估GBB通透性在心血管和代谢疾病中可能具有显著的诊断潜力。其次，我们认为GBB通透性是一个会混淆新的肠道微生物群衍生生物标志物（如TMAO）诊断价值的变量。因此，心血管风险评估需要同时评估TMAO和GBB通透性。
